The Korean Journal of Medicine

The Korean Association of Internal Medicine (대한내과학회)
권호 표지
DOI QR코드

DOI QR Code

Common Infectious Diseases in Hematopoietic Stem Cell Transplant Recipients

조혈모세포이식 환자에서 흔히 보는 감염

  • Lee, Dong-Gun (Division of Infectious Diseases, Department of Internal Medicine, The Catholic Blood and Marrow Transplantation Center, The Catholic University of Korea College of Medicine)
  • 이동건 (가톨릭대학교 의과대학 감염내과, 가톨릭 조혈모세포이식센터)
  • Published : 2013.02.01
⟨ Previous Next ⟩

Abstract

Hematopoietic stem cell transplantation (HSCT) has improved the outcome of numerous malignant and non-malignant diseases. However, infectious diseases (IDs) still contributes the burden of morbidity and mortality significantly after both autologous and allogeneic HSCTs. IDs are usually classified by the time periods after HSCT; pre-engraftment period, immediate and late post-engraftment period. Kinds of IDs and their frequencies and distribution are dependent not only on the stem cell sources, conditioning regimens, presence of graft-versus-host diseases, but also on the region, prophylactic antibiotics, and so on. In this article, the common IDs after HSCT according to the time periods are reviewed. Additionally, it is tried to focus the recent Korean perspectives, for examples, tuberculosis, herpes zoster, respiratory virus infection-especially hope to be of help for the non-transplant specialists and/or primary physicians.

Keywords

References

  1. Wingard JR, Hsu J, Hiemenz JW. Hematopoietic stem cell transplantation: an overview of infection risks and epidemiology. Infect Dis Clin North Am 2010;24:257-272. https://doi.org/10.1016/j.idc.2010.01.010
  2. Dropulic LK, Lederman HM. Overview of infections in the immunocompromised host. In: Hayden RT, Carroll KC, Tang YW, Wolk DM, eds. Diagnostic Microbiology of the Immunocompromised Host. 1st ed. Washinton, DC: ASM Press, 2009:3-43.
  3. Tomblyn M, Chiller T, Einsele H, et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant 2009;15:1143-1238. https://doi.org/10.1016/j.bbmt.2009.06.019
  4. Safdar A, Armstrong D. Infections in patients with hematologic neoplasms and hematopoietic stem cell transplantation: neutropenia, humoral, and splenic defects. Clin Infect Dis 2011;53:798-806. https://doi.org/10.1093/cid/cir492
  5. Lee JW, Kim CC. The activity of hematopoietic stem cell transplantation in Korea. Bone Marrow Transplant 2008; 42(Suppl 1):S92-95. https://doi.org/10.1038/bmt.2008.127
  6. Lee DG, Kim SH, Kim SY, et al. Evidence-based guidelines for empirical therapy of neutropenic fever in Korea. Korean J Intern Med 2011;26:220-252. https://doi.org/10.3904/kjim.2011.26.2.220
  7. Jun HX, Zhixiang S, Chun W, et al. Clinical guidelines for the management of cancer patients with neutropenia and unexplained fever. Int J Antimicrob Agents 2005;26(Suppl 2): S128-132. https://doi.org/10.1016/j.ijantimicag.2005.08.007
  8. Choi SM, Lee DG, Park YH, et al. Infections in patients with acute leukemia: comparison of induction chemotherapy group and reinduction chemotherapy group. Infect Chemother 2003;35:78-85.
  9. Kim HB, Park SW, Kim US, et al. Infections in Patients with Acute Leukemia (1993-1996). Korean J Hematol 1999;34: 359-365.
  10. Yoo JH, Lee DG, Choi SM, et al. Infectious complications and outcomes after allogeneic hematopoietic stem cell trans plantation in Korea. Bone Marrow Transplant 2004;34: 497-504. https://doi.org/10.1038/sj.bmt.1704636
  11. Park SH, Choi SM, Lee DG, et al. Current trends of infectious complications following hematopoietic stem cell transplantation in a single center. J Korean Med Sci 2006; 21:199-207.
  12. Kim SH, Kee SY, Lee DG, et al. Infectious complications following allogeneic stem cell transplantation: reduced-intensity vs. myeloablative conditioning regimens. Transpl Infect Dis 2012 Sep 24 [Epub]. http://dx.doi.org/10.1111/ tid.12003.
  13. Kwon JC, Kim SH, Choi JK, et al. Epidemiology and clinical features of bloodstream infections in hematology wards: one year experience at the Catholic blood and marrow transplantation center. Infect Chemother 2013 [in press].
  14. Freifeld AG, Bow EJ, Sepkowitz KA , et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of America. Clin Infect Dis 2011;52:e56-93. https://doi.org/10.1093/cid/cir073
  15. Leventakos K, Lewis RE, Kontoyiannis DP. Fungal infections in leukemia patients: how do we prevent and treat them? Clin Infect Dis 2010;50:405-415. https://doi.org/10.1086/649879
  16. Pappas PG, Kauffman CA, Andes D, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009;48:503-535. https://doi.org/10.1086/596757
  17. De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008;46:1813-1821. https://doi.org/10.1086/588660
  18. Marchetti O, Lamoth F, Mikulska M, Viscoli C, Verweij P, Bretagne S. ECIL recommendations for the use of biological markers for the diagnosis of invasive fungal diseases in leukemic patients and hematopoietic SCT recipients. Bone Marrow Transplant 2012;47:846-854. https://doi.org/10.1038/bmt.2011.178
  19. Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008;46: 327-360. https://doi.org/10.1086/525258
  20. Michallet M, Ito JI. Approaches to the management of invasive fungal infections in hematologic malignancy and hematopoietic cell transplantation. J Clin Oncol 2009;27: 3398-3409. https://doi.org/10.1200/JCO.2008.20.1178
  21. Maschmeyer G, Beinert T, Buchheidt D, et al. Diagnosis and antimicrobial therapy of lung infiltrates in febrile neutropenic patients: guidelines of the infectious diseases working party of the German Society of Haematology and Oncology. Eur J Cancer 2009;45:2462-2472. https://doi.org/10.1016/j.ejca.2009.05.001
  22. Pagano L, Caira M, Valentini CG, Posteraro B, Fianchi L. Current therapeutic approaches to fungal infections in immunocompromised hematological patients. Blood Rev 2010;24:51-61. https://doi.org/10.1016/j.blre.2009.11.003
  23. Maertens J, Marchetti O, Herbrecht R, et al. European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3: 2009 update. Bone Marrow Transplant 2011;46: 709-718. https://doi.org/10.1038/bmt.2010.175
  24. Choi SM, Park SH, Lee DG, Choi JH, Yoo JH, Shin WS. Current antimicrobial usage for the management of neutropenic fever in Korea: a nationwide survey. J Korean Med Sci 2008;23:941-947. https://doi.org/10.3346/jkms.2008.23.6.941
  25. Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002;347:408-415. https://doi.org/10.1056/NEJMoa020191
  26. Upton A, Kirby KA, Carpenter P, Boeckh M, Marr KA. Invasive aspergillosis following hematopoietic cell transplantation: outcomes and prognostic factors associated with mortality. Clin Infect Dis 2007;44:531-540. https://doi.org/10.1086/510592
  27. Schubert MM, Peterson DE, Flournoy N, Meyers JD, Truelove EL. Oral and pharyngeal herpes simplex virus infection after allogeneic bone marrow transplantation: analysis of factors associated with infection. Oral Surg Oral Med Oral Pathol 1990;70:286-293. https://doi.org/10.1016/0030-4220(90)90142-F
  28. Lee JT, Kim YT. Prevalence of antibody to herpes simplex virus. Korean J Dermatol 1993;31:38-46.
  29. Ljungman P, Griffiths P, Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 2002;34:1094-1097. https://doi.org/10.1086/339329
  30. Ljungman P, Reusser P, de la Camara R, et al. Management of CMV infections: recommendations from the infectious diseases working party of the EBMT. Bone Marrow Transplant 2004;33:1075-1081. https://doi.org/10.1038/sj.bmt.1704505
  31. Choi SM, Lee DG, Lim J, et al. Comparison of quantitative cytomegalovirus real-time PCR in whole blood and pp65 antigenemia assay: clinical utility of CMV real-time PCR in hematopoietic stem cell transplant recipients. J Korean Med Sci 2009;24:571-578. https://doi.org/10.3346/jkms.2009.24.4.571
  32. Choi SM, Lee DG, Choi JH, et al. Risk-adapted preemptive therapy for cytomegalovirus disease after allogeneic stem cell transplantation: a single-center experience in Korea. Int J Hematol 2005;81:69-74. https://doi.org/10.1532/IJH97.A30402
  33. Choi SM, Lee DG, Park SH, et al. Characteristics of cytomegalovirus diseases among hematopoietic stem cell transplant recipients: a 10-year experience at an university hospital in Korea. Infect Chemother 2009;41:9-19. https://doi.org/10.3947/ic.2009.41.1.9
  34. Jeon S, Lee WK, Lee Y, Lee DG, Lee JW. Risk factors for cytomegalovirus retinitis in patients with cytomegalovirus viremia after hematopoietic stem cell transplantation. Ophthalmology 2012;119:1892-1898. https://doi.org/10.1016/j.ophtha.2012.03.032
  35. Park SH, Choi SM, Lee DG, et al. Infectious complications associated with alemtuzumab use for allogeneic hematopoietic stem cell transplantation: comparison with anti- thymocyte globulin. Transpl Infect Dis 2009;11:413-423. https://doi.org/10.1111/j.1399-3062.2009.00414.x
  36. Bergeron A, Porcher R, Sulahian A, et al. The strategy for the diagnosis of invasive pulmonary aspergillosis should depend on both the underlying condition and the leukocyte count of patients with hematologic malignancies. Blood 2012;119:1831-1837. https://doi.org/10.1182/blood-2011-04-351601
  37. Ju JH, Choi JH, Lee DG, et al. Pneumocystis carinii pneumonia following stem cell transplantation. Korean J Infect Dis 2001;33:273-279.
  38. Park SH, Choi SM, Lee DG, et al. Clinical characteristics and outcomes of posttransplant lymphoproliferative disorders following allogeneic hematopoietic stem cell transplantation in Korea. J Korean Med Sci 2006;21:259-264. https://doi.org/10.3346/jkms.2006.21.2.259
  39. Kim YJ, Kim DW, Lee DG, et al. Human herpesvirus-6 as a possible cause of encephalitis and hemorrhagic cystitis after allogeneic hematopoietic stem cell transplantation. Leukemia 2002;16:958-959. https://doi.org/10.1038/sj.leu.2402403
  40. Dropulic LK, Jones RJ. Polyomavirus BK infection in blood and marrow transplant recipients. Bone Marrow Transplant 2008;41:11-18. https://doi.org/10.1038/sj.bmt.1705886
  41. Ison MG. Adenovirus infections in transplant recipients. Clin Infect Dis 2006;43:331-339. https://doi.org/10.1086/505498
  42. Leung AY, Suen CK, Lie AK, Liang RH, Yuen KY, Kwong YL. Quantification of polyoma BK viruria in hemorrhagic cystitis complicating bone marrow transplantation. Blood 2001;98:1971-1978. https://doi.org/10.1182/blood.V98.6.1971
  43. Erard V, Kim HW, Corey L, et al. BK DNA viral load in plasma: evidence for an association with hemorrhagic cystitis in allogeneic hematopoietic cell transplant recipients. Blood 2005;106:1130-1132. https://doi.org/10.1182/blood-2004-12-4988
  44. Kim SY, Lee JW, Lee KM, et al. Viruria in adult hemorrhagic cystitis patients following allogeneic hematopoietic stem cell transplantation and implication of antiviral treatment. Korean J Hematol 2007;42:114-121. https://doi.org/10.5045/kjh.2007.42.2.114
  45. Hammarstrom V, Pauksen K, Svensson H, et al. Serum immunoglobulin levels in relation to levels of specific antibodies in allogeneic and autologous bone marrow transplant recipients. Transplantation 2000;69:1582-1586.
  46. Lee DG, Yoo JH. Hematopoietic stem cell transplantation. In: Cheong HJ, ed. Vaccination for adults. 2nd ed. Seoul: MIP Press, 2012:380-388.
  47. Weigt SS, Gregson AL, Deng JC, Lynch JP 3rd, Belperio JA. Respiratory viral infections in hematopoietic stem cell and solid organ transplant recipients. Semin Respir Crit Care Med 2011;32:471-493. https://doi.org/10.1055/s-0031-1283286
  48. Kumar D, Humar A. Respiratory viral infections in transplant and oncology patients. Infect Dis Clin North Am 2010;24:395-412. https://doi.org/10.1016/j.idc.2010.01.007
  49. Campbell AP, Chien JW, Kuypers J, et al. Respiratory virus pneumonia after hematopoietic cell transplantation (HCT): associations between viral load in bronchoalveolar lavage samples, viral RNA detection in serum samples, and clinical outcomes of HCT. J Infect Dis 2010;201:1404-1413. https://doi.org/10.1086/651662
  50. Lee DG, Park ST, Na BK, et al. Characteristics of respiratory tract infection in the hematopoietic stem cell transplantation population. Korean J Infect Dis 2001;33:419-429.
  51. Choi WS, Noh JY, Huh JY, et al. Seroprevalence of varicella- zoster virus in Korea. J Med Virol 2010;82:2123-2126. https://doi.org/10.1002/jmv.21917
  52. Kim DH, Kumar D, Messner HA, et al. Clinical efficacy of prophylactic strategy of long-term low-dose acyclovir for Varicella-Zoster virus infection after allogeneic peripheral blood stem cell transplantation. Clin Transplant 2008;22: 770-779. https://doi.org/10.1111/j.1399-0012.2008.00877.x
  53. Russo RL, Dulley FL, Suganuma L, França IL, Yasuda MA, Costa SF. Tuberculosis in hematopoietic stem cell transplant patients: case report and review of the literature. Int J Infect Dis 2010;14(Suppl 3):e187-191.
  54. Lee J, Lee MH, Kim WS, et al. Tuberculosis in hematopoietic stem cell transplant recipients in Korea. Int J Hematol 2004;79:185-188. https://doi.org/10.1532/IJH97.A10219
  55. Joint Committee for the Development of Korean Guidelines for Tuberculosis, Korea Centers for Disease Control and Prevention. Korean Guidelines for Tuberculosis [Internet]. Seoul: Joint Committee for the Development of Korean Guidelines for Tuberculosis, Korea Centers for Disease Control and Prevention, c2011 [cited Jan 28 2013]. Available from:http://www.lungkorea.org/thesis/file/결핵진료지침-최종20110608.pdf.

Cited by

  1. Vaccination of Hematopoietic Stem Cell Transplantation Recipients: Perspective in Korea vol.45, pp.3, 2013, https://doi.org/10.3947/ic.2013.45.3.272
  2. The demanding attention of tuberculosis in allogeneic hematopoietic stem cell transplantation recipients: High incidence compared with general population vol.12, pp.3, 2013, https://doi.org/10.1371/journal.pone.0173250
  3. Lower Respiratory Tract Diseases Caused by Common Respiratory Viruses among Stem Cell Transplantation Recipients: A Single Center Experience in Korea vol.58, pp.2, 2013, https://doi.org/10.3349/ymj.2017.58.2.362
  4. Varicella zoster virus infection after allogeneic hematopoietic cell transplantation in children using a relatively short duration of acyclovir prophylaxis : A retrospective study vol.96, pp.14, 2013, https://doi.org/10.1097/md.0000000000006546
  5. Infectious complications after hematopoietic stem cell transplantation: current status and future perspectives in Korea vol.33, pp.2, 2013, https://doi.org/10.3904/kjim.2018.036